Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 10/2009

01.10.2009 | Original Article

Activation of tumor-specific T lymphocytes after laser-induced thermotherapy in patients with colorectal liver metastases

verfasst von: Thomas Josef Vogl, Thaddäus T. Wissniowski, Nagy N. N. Naguib, Renate M. Hammerstingl, Martin G. Mack, Sabine Münch, Matthias Ocker, Deike Strobel, Eckhart G. Hahn, Johannes Hänsler

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 10/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To asses if laser-induced thermotherapy (LITT) induces a specific cytotoxic T cell response in patients treated with LITT for colorectal cancer liver metastases.

Methods

Eleven patients with liver metastases of colorectal cancer underwent LITT. Blood was sampled before and after LITT. Peripheral T cell activation was assessed by an interferon gamma (IFNg) secretion assay and flow cytometry. Test antigens were autologous liver and tumor lysate obtained from each patient by biopsy. T cells were stained for CD3/CD4/CD8 and IFNg to detect activated T cells. The ratio of IFNg positive to IFNg negative T cells was determined as the stimulation index (SI). To assess cytolytic activity, T cells were co-incubated with human colorectal cancer cells (CaCo) and cytosolic adenylate kinase release was measured by a luciferase assay.

Results

IFNg secretion assay: before LITT SI was 12.73 (±4.83) for CD3+, 4.36 (±3.32) for CD4+ and 3.64 (±1.77) for CD8+ T cells against autologous tumor tissue. Four weeks after LITT SI had increased to 92.09 (±12.04) for CD3+ (P < 0.001), 42.92 (±16.68) for CD4+ (P < 0.001) and 47.54 (±15.68) for CD8+ T cells (P < 0.001) against autologous tumor tissue. No increased SI was observed with normal liver tissue at any time point. Cytotoxicity assay: before LITT activity against the respective cancer cells was low, with RLU = 1,493 (±1,954.68), whereas after LITT cytolytic activity had increased to RLU = 7,260 [±3,929.76 (P < 0.001)].

Conclusion

Patients with liver metastases of colorectal cancer show a tumor-specific cytotoxic T cell stimulation and a significantly increased cytolytic activity of CD3+, CD4+ and CD8+ T cells after LITT against an allogenic tumor (CaCo cell line).
Literatur
1.
Zurück zum Zitat Jiang HC, Liu LX, Piao DX, Xu J, Zheng M, Zhu AL, Qi SY, Zhang WH, Wu LF (2002) Clinical short-term results of radiofrequency ablation in liver cancers. World J Gastroenterol 8(4):624–630PubMed Jiang HC, Liu LX, Piao DX, Xu J, Zheng M, Zhu AL, Qi SY, Zhang WH, Wu LF (2002) Clinical short-term results of radiofrequency ablation in liver cancers. World J Gastroenterol 8(4):624–630PubMed
2.
Zurück zum Zitat Vogl TJ, Straub R, Eichler K, Söllner O, Mack MG (2004) Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy—local tumor control rate and survival data. Radiology 230:450–458PubMedCrossRef Vogl TJ, Straub R, Eichler K, Söllner O, Mack MG (2004) Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy—local tumor control rate and survival data. Radiology 230:450–458PubMedCrossRef
3.
Zurück zum Zitat Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221(1):159–166PubMedCrossRef Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, Cova L, Halpern EF, Gazelle GS (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 221(1):159–166PubMedCrossRef
4.
Zurück zum Zitat Hansler J, Wissniowski TT, Schuppan D, Witte A, Bernatik T, Hahn EG, Strobel D (2006) Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 12(23):3716–3721PubMed Hansler J, Wissniowski TT, Schuppan D, Witte A, Bernatik T, Hahn EG, Strobel D (2006) Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol 12(23):3716–3721PubMed
5.
Zurück zum Zitat Wissniowski TT, Hansler J, Neureiter D, Frieser M, Schaber S, Esslinger B, Voll R, Strobel D, Hahn EG, Schuppan D (2003) Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res 63(19):6496–6500PubMed Wissniowski TT, Hansler J, Neureiter D, Frieser M, Schaber S, Esslinger B, Voll R, Strobel D, Hahn EG, Schuppan D (2003) Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res 63(19):6496–6500PubMed
6.
Zurück zum Zitat Isbert C, Ritz JP, Roggan A, Schuppan D, Rühl M, Buhr HJ, Germer CT (2004) Enhancement of the immune response to residual intrahepatic tumor tissue by laser-induced thermotherapy (LITT) compared to hepatic resection. Lasers Surg Med 35:284–292PubMedCrossRef Isbert C, Ritz JP, Roggan A, Schuppan D, Rühl M, Buhr HJ, Germer CT (2004) Enhancement of the immune response to residual intrahepatic tumor tissue by laser-induced thermotherapy (LITT) compared to hepatic resection. Lasers Surg Med 35:284–292PubMedCrossRef
7.
Zurück zum Zitat Ivarsson K, Myllymäki L, Jansner K, Stenram U, Tranberg KG (2005) Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response. Br J Cancer 93:435–440PubMedCrossRef Ivarsson K, Myllymäki L, Jansner K, Stenram U, Tranberg KG (2005) Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response. Br J Cancer 93:435–440PubMedCrossRef
8.
Zurück zum Zitat Frezza EE, Wachtel MS, Barragan B, Chiriva-Internati M, Cobos E (2007) The role of radiofrequency ablation in multiple liver metastases to debulk the tumor: a pilot study before alternative therapies. J Laparoendosc Adv Surg Tech A 17(3):282–284PubMedCrossRef Frezza EE, Wachtel MS, Barragan B, Chiriva-Internati M, Cobos E (2007) The role of radiofrequency ablation in multiple liver metastases to debulk the tumor: a pilot study before alternative therapies. J Laparoendosc Adv Surg Tech A 17(3):282–284PubMedCrossRef
9.
Zurück zum Zitat Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236PubMedCrossRef Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236PubMedCrossRef
10.
Zurück zum Zitat Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J, EASL Panel of Experts on HCC (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430PubMedCrossRef Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J, EASL Panel of Experts on HCC (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430PubMedCrossRef
11.
Zurück zum Zitat Helmberger T, Dogan S, Straub G, Schrader A, Jüngst C, Reiser M, Waggershauser T, Jakobs T, Hoffmann RT, Löhe F, Graeb C, Rau HG, Schauer R, Jauch KW, Caselmann WH, Göke B, Jüngst D (2007) Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. Digestion 75(2–3):104–112PubMedCrossRef Helmberger T, Dogan S, Straub G, Schrader A, Jüngst C, Reiser M, Waggershauser T, Jakobs T, Hoffmann RT, Löhe F, Graeb C, Rau HG, Schauer R, Jauch KW, Caselmann WH, Göke B, Jüngst D (2007) Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. Digestion 75(2–3):104–112PubMedCrossRef
12.
Zurück zum Zitat Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS (2001) Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology 220(1):145–149PubMed Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS (2001) Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology 220(1):145–149PubMed
13.
Zurück zum Zitat Solbiati L, Ierace T, Tonolini M, Osti V, Cova L (2001) Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound 13(2):149–158PubMedCrossRef Solbiati L, Ierace T, Tonolini M, Osti V, Cova L (2001) Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound 13(2):149–158PubMedCrossRef
14.
Zurück zum Zitat Gazelle GS, Goldberg SN, Solbiati L, Livraghi T (2000) Tumor ablation with radio-frequency energy. Radiology 217(3):633–646PubMed Gazelle GS, Goldberg SN, Solbiati L, Livraghi T (2000) Tumor ablation with radio-frequency energy. Radiology 217(3):633–646PubMed
15.
Zurück zum Zitat Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–321PubMedCrossRef Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–321PubMedCrossRef
16.
Zurück zum Zitat Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766PubMedCrossRef Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766PubMedCrossRef
17.
Zurück zum Zitat Mutsaerts EL, van Ruth S, Zoetmulder FA, Rutgers EJ, Hart AA, van Coevorden F (2005) Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience. J Gastrointest Surg 9:178–186PubMedCrossRef Mutsaerts EL, van Ruth S, Zoetmulder FA, Rutgers EJ, Hart AA, van Coevorden F (2005) Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience. J Gastrointest Surg 9:178–186PubMedCrossRef
18.
Zurück zum Zitat Masters A, Steger AC, Lees WR, Walmsley KM, Bown SG (1992) Interstitial laser hyperthermia: a new approach for treating liver metastases. Br J Cancer 66:518–522PubMed Masters A, Steger AC, Lees WR, Walmsley KM, Bown SG (1992) Interstitial laser hyperthermia: a new approach for treating liver metastases. Br J Cancer 66:518–522PubMed
19.
Zurück zum Zitat Nolsoe CP, Torp-Pedersen S, Burcharth F, Horn T, Pedersen S, Christensen NE, Olldag ES, Andersen PH, Karstrup S, Lorentzen T (1993) Interstitial hyperthermia of colorectal liver metastases with a US-guided Nd-YAG laser with a diffuser tip: a pilot clinical study. Radiology 187:333–337PubMed Nolsoe CP, Torp-Pedersen S, Burcharth F, Horn T, Pedersen S, Christensen NE, Olldag ES, Andersen PH, Karstrup S, Lorentzen T (1993) Interstitial hyperthermia of colorectal liver metastases with a US-guided Nd-YAG laser with a diffuser tip: a pilot clinical study. Radiology 187:333–337PubMed
20.
Zurück zum Zitat Schroder T, Castren-Persons M, Lehtinen A, Taavitsainen M (1994) Percutaneous interstitial laser hyperthermia in clinical use. Ann Chir Gynaecol 83:286–290PubMed Schroder T, Castren-Persons M, Lehtinen A, Taavitsainen M (1994) Percutaneous interstitial laser hyperthermia in clinical use. Ann Chir Gynaecol 83:286–290PubMed
21.
Zurück zum Zitat Muralidharan V, Christophi C (2001) Interstitial laser thermotherapy in the treatment of colorectal liver metastases. J Surg Oncol 76:73–81PubMedCrossRef Muralidharan V, Christophi C (2001) Interstitial laser thermotherapy in the treatment of colorectal liver metastases. J Surg Oncol 76:73–81PubMedCrossRef
22.
Zurück zum Zitat Jacques SL (1992) Laser–tissue interactions. Photochemical, photothermal, and photomechanical. Surg Clin North Am 72(3):531–558 (review)PubMed Jacques SL (1992) Laser–tissue interactions. Photochemical, photothermal, and photomechanical. Surg Clin North Am 72(3):531–558 (review)PubMed
23.
Zurück zum Zitat Zerbini A, Pilli M, Penna A, Orlandini A, Mezzadri S, Sacchelli L, Missale G, Ferrari C (2006) Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 66(2):1139–1146PubMedCrossRef Zerbini A, Pilli M, Penna A, Orlandini A, Mezzadri S, Sacchelli L, Missale G, Ferrari C (2006) Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 66(2):1139–1146PubMedCrossRef
24.
Zurück zum Zitat den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, Adema GJ (2004) In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64(11):4024–4029CrossRef den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, Adema GJ (2004) In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64(11):4024–4029CrossRef
Metadaten
Titel
Activation of tumor-specific T lymphocytes after laser-induced thermotherapy in patients with colorectal liver metastases
verfasst von
Thomas Josef Vogl
Thaddäus T. Wissniowski
Nagy N. N. Naguib
Renate M. Hammerstingl
Martin G. Mack
Sabine Münch
Matthias Ocker
Deike Strobel
Eckhart G. Hahn
Johannes Hänsler
Publikationsdatum
01.10.2009
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 10/2009
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0663-1

Weitere Artikel der Ausgabe 10/2009

Cancer Immunology, Immunotherapy 10/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.